According to Zhito Financial APP, Sailun Biotechnology (688163.SH) announced that its joint venture Shanghai Saiyuen Biotechnology Co., Ltd. (abbreviated as "Saiyuen Biotechnology") has decided to suspend the clinical research of the "Anmeimu Monoclonal Antibody" project. To more objectively and fairly reflect the company's financial condition and asset value, and in accordance with the Ministry of Finance's "Accounting Standards for Business Enterprises No. 2 - Long-term Private Equity Investment" and "Accounting Standards for Business Enterprises No. 8 - Asset Impairment" and the company's accounting policies, combined with the actual operation situation and asset status of the long-term private equity investment enterprise, in the spirit of prudence, the company will fully provision for impairment for its long-term private equity investment in the joint venture Saiyuen Biotechnology.

According to the preliminary estimate of the company's consolidated financial statements as of October 31, 2024, the company will completely provision for impairment on the long-term private equity investment in Saiyuen Biotechnology and confirm an estimated investment loss amount of 14.1448 million yuan, resulting in a post-provisioning book balance of zero for this long-term private equity investment.